<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404585</url>
  </required_header>
  <id_info>
    <org_study_id>IM126-004</org_study_id>
    <secondary_id>2011-002024-40</secondary_id>
    <nct_id>NCT01404585</nct_id>
  </id_info>
  <brief_title>Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis</brief_title>
  <acronym>RA</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether BMS-817399 in combination with Methotrexate is&#xD;
      effective in treating moderate to severe rheumatoid arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) change from baseline of BMS-817399 versus placebo</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, physical examinations, and clinical laboratory tests</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 20% American College of Rheumatology (ACR) response in each treatment group</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 20% ACR response in each treatment group</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 20% ACR response in each treatment group</measure>
    <time_frame>Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 20% ACR response in each treatment group</measure>
    <time_frame>Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 50% ACR response in each treatment group</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 50% ACR response in each treatment group</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 50% ACR response in each treatment group</measure>
    <time_frame>Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 50% ACR response in each treatment group</measure>
    <time_frame>Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 70% ACR response in each treatment group</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 70% ACR response in each treatment group</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 70% ACR response in each treatment group</measure>
    <time_frame>Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 70% ACR response in each treatment group</measure>
    <time_frame>Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>Baseline and Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>Baseline and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>Baseline and Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>Baseline and Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the minimum observed concentration (Cmin) of BMS-817399</measure>
    <time_frame>Day 15, Day 29, Day 57 and Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: BMS-817399 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: BMS-817399 (400 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, twice daily, 12 weeks</description>
    <arm_group_label>Arm 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-817399</intervention_name>
    <description>Tablets, Oral, 200 mg, twice daily, 12 weeks</description>
    <arm_group_label>Arm 2: BMS-817399 (200 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-817399</intervention_name>
    <description>Tablets, Oral, 400mg, twice daily, 12 weeks</description>
    <arm_group_label>Arm 3: BMS-817399 (400 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 18 years of age or older, with rheumatoid arthritis (RA) for&#xD;
             at least 6 months prior to screening&#xD;
&#xD;
          -  Subjects must have a tender joint count of at least 6 (28 joint count), swollen joint&#xD;
             count of at least 6 (28 joint count) at screening. All subjects must have clinical&#xD;
             evidence of synovitis in one hand/wrist at screening&#xD;
&#xD;
          -  Serum C-reactive protein (hsCRP) above upper limits of normal at screening&#xD;
&#xD;
          -  Subjects must have been treated with and tolerated Methotrexate (MTX) therapy at a&#xD;
             weekly oral or parenteral dose ≥ 10 mg for ≥ 4 months prior to screening. Dose must be&#xD;
             stable, with no change in route of administration, for ≥ 6 weeks prior to&#xD;
             randomization. A MTX weekly dose as low as 7.5 mg is permitted if intolerance to doses&#xD;
             ≥10 mg has been documented in the subject's medical history&#xD;
&#xD;
          -  Subjects must be receiving folic acid, folinic acid, or leucovorin supplementation at&#xD;
             a stable dose for at least 4 weeks prior to randomization&#xD;
&#xD;
          -  Subjects who were previously treated with up to two tumor necrosis factor α (TNF-α)&#xD;
             inhibitors&#xD;
&#xD;
          -  If taking antimalarials (e.g. hydroxychloroquine or chloroquine), subject must have&#xD;
             been on a stable dose for ≥ 4 months prior to randomization&#xD;
&#xD;
          -  If taking non-steroidal anti-inflammatory drugs (NSAIDs), subjects must have been on&#xD;
             stable doses for ≥ 2 weeks prior to randomization&#xD;
&#xD;
          -  If taking oral corticosteroids, daily doses must be ≤ 10 mg/day of prednisone or&#xD;
             equivalent and stable for ≥ 4 weeks before randomization&#xD;
&#xD;
          -  Subject is willing to participate to the study and has signed the informed consent&#xD;
             prior to undergoing any screening procedures&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and men must agree to use at least two&#xD;
             acceptable methods to avoid pregnancy for the entire study period and until 60 days&#xD;
             (for women) and 90 days (for men) after the last dose of BMS-817399. WOCBP must have a&#xD;
             negative urine pregnancy test at screening, randomization and at scheduled visits&#xD;
             throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Arthritis onset prior to 16 years of age or subjects with documented juvenile RA&#xD;
&#xD;
          -  Subjects who are bed- or wheelchair-bound&#xD;
&#xD;
          -  Subjects with other autoimmune diseases or arthritis syndromes&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding or with a positive pregnancy test at screening&#xD;
             or prior to randomization&#xD;
&#xD;
          -  Subjects who have any condition that could impact upon the absorption of study drug&#xD;
             (i.e., gastric stapling, duodenal surgery, malabsorption syndrome)&#xD;
&#xD;
          -  Subjects with a history of, or a concurrent severe, progressive, or uncontrolled&#xD;
             disease (other than RA) that in the opinion of the investigator might place the&#xD;
             subject at unacceptable risk for participation in this study&#xD;
&#xD;
          -  Subjects who have present or previous (last 5 years) malignancies, except history of&#xD;
             cured squamous or basal skin cell carcinoma or cured breast or cervical cancer&#xD;
&#xD;
          -  Subjects at risk for tuberculosis (TB) or with evidence of TB clinical history, chest&#xD;
             X rays or tuberculin skin test&#xD;
&#xD;
          -  Subjects with evidence of active or latent bacterial or viral infections (including&#xD;
             human immunodeficiency virus); Positive blood screen for hepatitis B surface antigen&#xD;
             or hepatitis C antibody&#xD;
&#xD;
          -  Subjects with any serious bacterial infection within the last 2 months, unless treated&#xD;
             and resolved with antibiotics&#xD;
&#xD;
          -  Subjects who have clinically significant drug or alcohol abuse or known cirrhosis&#xD;
             including alcoholic cirrhosis&#xD;
&#xD;
          -  If a subject has received any of the following treatments, the indicated washout&#xD;
             period prior to randomization must be followed:&#xD;
&#xD;
               1. Oral or injectable azathioprine, gold, D-Penicillamine, cyclosporine, anakinra,&#xD;
                  etanercept, parenteral or intra-articular corticosteroids: 30 days&#xD;
&#xD;
               2. Leflunomide: 6 months unless an active washout with Cholestyramine has been&#xD;
                  performed&#xD;
&#xD;
               3. Mycophenolate mofetil, cyclophosphamide, tacrolimus or other immunosuppressant: 3&#xD;
                  months&#xD;
&#xD;
               4. Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Abatacept or Tocilizumab:&#xD;
                  60 days&#xD;
&#xD;
               5. Rituximab or any B-cell depleting agent: 1 year&#xD;
&#xD;
          -  Use CYP3A4 inhibitors or inducers during the study&#xD;
&#xD;
          -  Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥&#xD;
             1.5x upper limit of normal (ULN), total bilirubin ≥ 1.4x ULN, estimated glomerular&#xD;
             filtration rate (GFR) &lt; 50 mL/min/1.73m2, hemoglobin &lt; 10.0 g/dL, white blood cell&#xD;
             count &lt; 3,500/mm3, absolute neutrophil count &lt; 1,700/mm3 or platelets &lt; 125,000/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, Llc</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharma Resource</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1015</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>D.f.</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44158</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Panorama</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pinelands</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2011</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2015</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

